Drug investigator David Nutt, a longtime thorn in the side of U.K. officials, is back at his favorite pastime. Nutt was kicked out of his post as an official adviser to the government on therapeutics after adopting a controversial stance in favor of testing illicit drugs like magic mushrooms for depression. And now he says "insane" government rules have blocked manufacturers from signing on to supply psilocybin for an approved clinical study.
Everyone who's anyone in Big Pharma wants to amp up in orphan drugs. Treatments for rare disorders, many of them deadly, aren't easily copied, and competitors are few, if not completely absent. Plus, payers are willing to pay top dollar for drugs aimed at very small groups of patients. Even if they are costly.
TranScrip Partners is coming to America, as the U.K.-based CRO is opening its first stateside office to expand its global footprint.
Academia is increasingly realizing the medical and financial possibilities that building persona lized medicine programs can bring. Case in point: The Perelman School of Medicine at the University of Pennsylvania this year has unveiled the Center for Personalized Diagnostics, a joint initiative from the school's department of Pathology and Laboratory medicine and the Abramson Cancer Center.
Scientists at University Paris Descartes in Paris, France, identified biomarkers in non-small cell lung cancer cells that prove resistant to the chemotherapy drug cisplatin.
Most types of diagnostic imaging equipment carry a basic rule: Patients must stay still. That can create care challenges for children, the elderly or patients with neurodegenerative diseases, all of whom may need sedation or restraints to keep them from moving around. And in the case of brain scans, those added aids can trigger added brain activity that can skew imaging results.
Bristol-Myers Squibb has reached into its R&D organization to find a replacement for R&D chief Elliott Sigal, the latest in a string of biopharma research chiefs to find himself facing an early retirement.
Oxford researchers have developed a 3-D printer that produces synthetic tissue made from oil and water.
CROs competing for big-name deals may face a more crowded market now that on-the-ropes diagnostics companies are getting into the clinical research game, something LabCorp demonstrated this week as it inked a preferred-provider contract with Bristol-Myers Squibb.
Vertex Pharmaceuticals has found another ally as the company plays catch up in the race to advance all-oral therapies against hepatitis C. Vertex and Bristol-Myers Squibb have agreed to combine experimental compounds to test in Phase II trials, the first of which will kick off during the current fiscal quarter.